Altimmune's Pemvidutide Gets FDA Breakthrough Status for MASH, Bolstered by $274M Cash
ALT sits 46% above its 52-week low of $2.9.
Summary
Altimmune announced its fourth quarter and full-year 2025 financial results alongside significant business updates. The most impactful news is the FDA granting Breakthrough Therapy Designation for its lead candidate, pemvidutide, in Metabolic Dysfunction-Associated Steatohepatitis (MASH). This designation is a major positive, as it can expedite the development and regulatory review process for pemvidutide, a potential blockbuster drug in a large market, based on preliminary clinical evidence suggesting substantial improvement over available therapies. The company also reported a strong cash position of $274 million as of December 31, 2025, further strengthened by a $75 million registered direct offering in January 2026. This robust cash balance provides significant financial runway to support the planned initiation of the Phase 3 MASH trial in 2026, reducing immediate financing concerns. Investors will now focus on the progress of the Phase 3 MASH trial and the upcoming topline data from the RECLAIM Phase 2 trial of pemvidutide in alcohol use disorder (AUD), expected in Q3 2026, which represents another significant catalyst.
At the time of this announcement, ALT was trading at $4.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $534.7M. The 52-week trading range was $2.90 to $7.73. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.